Karo Bio Initiates Phase IIb Clinical Study with KB2115

14 November - Karo Bio has received approval for initiation of a Phase IIb clinical study with KB2115. This study will be conducted in dyslipidemia patients receiving concomitant statin treatment. Patient recruitment has been initiated for the three month study which in total will include 172 patients. Read more 

Novel Agent for Treatment of Parkinson's Disease in Clinical Development

13 November - Lundbeck has initiated Phase I clinical trials with the pharmaceutical candidate Lu AA47070 to investigate safety, tolerability and the pharmacokinetic profile of the compound in humans. It is expected that Lu AA47070 may have a potential in certain neurological indications. Read more

Genmab to Present Zanolimumab and Ofatumumab Data at ASH

9 November - Genmab A/S has announced that additional positive results have been obtained in the Phase II study to treat patients with relapsed or refractory NCTCL. The clinical data will be presented at the 2007 Annual Meeting of the American Society of Hematology on 8-11 December in Atlanta, Georgia, USA. Read more

Promising Clinical Results from New HIV Vaccine 

9 November - At the fall meeting of the HIV Vaccine Trials Network, Pharmexa announced preliminary results from the HVTN 064 Phase I trial of Pharmexa's epitope based recombinant protein vaccine EP1043, which was tested alone and in combination with Pharmexa's epitope based DNA vaccine EP1090. Read more